Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma

Journal of B.U.ON.

Volumn 16, Issue 1, 2011, Pages 9-15

  Motta, G ^a   Cea, M ^a   Carbone, F ^a   Augusti, V ^a   Moran, E ^a   Patrone, F ^a   Nencioni, Alessio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Apoptosis; Chemotherapy; Lymphoma; Monoclonal antibodies; Rituximab

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; LUMILIXIMAB; MELPHALAN; MITOXANTRONE; OFATUMUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; APLASTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW HYPOPLASIA; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY; HYPOTENSION; HYPOXIA; IMMUNOCHEMOTHERAPY; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; NONHODGKIN LYMPHOMA; PANCYTOPENIA; RADIOIMMUNOTHERAPY; REVIEW; SKIN MANIFESTATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 79954478611     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
2. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-843.
3. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58: 79-88; discussion 89-90.
4. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (idec-c2b8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186. (Pubitemid 27349961)
5. Petryk M, Grossbard ML. Rituximab therapy of B-cell neoplasms. Clin Lymphoma 2000; 1: 186-194; discussion 195-196.
6. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan BC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40: 259-263.
7. Walshe CA, S. Beers A, French RR et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem 2008; 283: 16971-16984.
8. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176-182. (Pubitemid 35279043)
9. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121: 1121-1132. (Pubitemid 23154272)
10. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. ImmunolToday 1995; 15: 450-454. (Pubitemid 24272191)
11. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446. (Pubitemid 30208162)
12. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-2143. (Pubitemid 40516580)
13. Bagust A, Boland A. Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess 2009; 13 (Suppl 2): 23-29.
14. Kimby E, Björkholm M, Gahrton G et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of central Sweden. Ann Oncol 1994; 5: (Suppl 2) 67-71.
15. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, GrilloLópez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-4716.
16. Czuczman MS, Koryzna A, Mohr A et al. C. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694-704. (Pubitemid 46224168)
17. Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
18. Hiddemann W, Buske C, Dreyling M et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005; 23: 6394-6399. (Pubitemid 46222239)
19. Domingo-Domènech E, González-Barca E, Estany C, Sureda A, Besalduch J, de Sevilla AF. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica 2002; 87: 1229-1230. (Pubitemid 35397786)
20. Pfreundschuh M, TrÜmper L, Osterborg A et al; M.I.N.T. Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mabthera international trial (MINT) group. Lancet Oncol 2006; 7: 379-391.
21. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 342: 235-242. (Pubitemid 34438862)
22. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110: 29-36. (Pubitemid 47026815)
23. Hainsworth JD, Litchy S, Barton JH et al; M.P.C.R. Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003 ; 21: 1746-1751. (Pubitemid 46638587)
24. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170. (Pubitemid 32366970)
25. Schulz H, Klein SK, Rehwald U et al; M.G.C.S. Group. Phase 2 study of a combined imrnunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-3120.
26. Lamanna N, Kalaycio M, Maslak P et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 1575-1581. (Pubitemid 46638781)
27. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078. (Pubitemid 46211312)
28. Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088. (Pubitemid 46211313)
29. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
30. Robak T, Dmoszynska A. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765.
31. Hainsworth JD, Litchy S, Burris HA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-4267. (Pubitemid 35191030)
32. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088-1095. (Pubitemid 46202263)
33. Habermann TM, Weiler EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127. (Pubitemid 46638950)
34. Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399-2404.
35. Nademanee A, Forman SJ. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma. Semin Hematol 2006; 43: 240-250. (Pubitemid 44486318)
36. Khouri IF, Saliba RM. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240-2247. (Pubitemid 46218716)
37. Witzens-Harig DP. Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 2010; 51: 967-974.
38. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833. (Pubitemid 28363048)
39. Kunkel L, Wong A, Maneatis T et al. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. Semin Oncol 2000; 27: 53-61. (Pubitemid 32166264)
40. Kennedy GA, Tey S-K, Cobcroft R et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002; 119: 412-416. (Pubitemid 35365492)
41. Czuczman MS, Olejniczak S. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pre-transcriptional and post-transcriptional levels. Clin Cancer Res 2008; 14: 1561-1570. (Pubitemid 351413941)
42. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased bax and bak expression. Clin Cancer Res 2008; 14: 1550-1560.
43. Stolz SM. Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009; 50: 873-885.
44. Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.Blood 2008; 111: 1094-1100. (Pubitemid 351213387)
45. Stein R, Qu Z, Chen S et al. Characterization of a new humanized anti-CD20 monoclonal antibody, immu-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 2868-2878. (Pubitemid 38509167)
46. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (campath-1h) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561. (Pubitemid 34534522)
47. Lundin J, Hagberg H, Repp R et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-4272. (Pubitemid 36857787)
48. Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920-2924. (Pubitemid 38451660)
49. Younes A, Hariharan K, Allen RS, Leigh BR. Initial trials of anti-CD80 monoclonal antibody (galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Clin Lymphoma 2003; 3: 257-259. (Pubitemid 36416853)
50. Vyth-Dreese FA, Dellemijn TA, Majoor D, de Jong D. Localization in situ of the co-stimulatory molecules b7.1, b7.2, CD40 and their ligands in normal human lymphoid tissue. Eur J Immunol 1995; 25: 3023-3029.
51. Munro JM, Freedman AS, Aster JC et al. In vivo expression of the b7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83: 793-798.
52. Leonard J, Friedberg J, Younes A et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007; 18: 1216-1223. (Pubitemid 47244369)
53. Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3051-3059. (Pubitemid 46606284)
54. Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004; 10: 5327-5334. (Pubitemid 39100467)
55. Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 115: 489-495.
56. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 6325-6332. (Pubitemid 46218842)
57. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of idec-y2b8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
58. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
59. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463. (Pubitemid 34525730)
60. Morschhause F, Illidge T, Huglo D et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54-58. (Pubitemid 47026818)
61. Horning SJ, Younes A, Jain V et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23: 712-719. (Pubitemid 46224170)
62. Press OW, Unger JM, Braziel RM et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine i-131 tosi-tumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911. J Clin Oncol 2006; 24: 4143-4149. (Pubitemid 46622291)